PlainRecalls
FDA Drug Moderate Class II Terminated

BUPRENORPHINE HYDROCHLORIDE Sublingual Tablets, 8 mg, 30-count bottles, Rx only, Teva Pharmaceuticals USA, Sellersville, PA 18960, NDC 0093-5379-56, UPC 3 0093-5379-56 2.

Reported: May 28, 2014 Initiated: April 7, 2014 #D-1325-2014

Product Description

BUPRENORPHINE HYDROCHLORIDE Sublingual Tablets, 8 mg, 30-count bottles, Rx only, Teva Pharmaceuticals USA, Sellersville, PA 18960, NDC 0093-5379-56, UPC 3 0093-5379-56 2.

Reason for Recall

Failed Impurities/Degradation Specifications: High out of specification impurity test results were obtained during stability testing.

Details

Recalling Firm
Teva Pharmaceuticals USA
Units Affected
53,452 bottles
Distribution
Nationwide and Puerto Rico
Location
North Wales, PA

Frequently Asked Questions

What product was recalled?
BUPRENORPHINE HYDROCHLORIDE Sublingual Tablets, 8 mg, 30-count bottles, Rx only, Teva Pharmaceuticals USA, Sellersville, PA 18960, NDC 0093-5379-56, UPC 3 0093-5379-56 2.. Recalled by Teva Pharmaceuticals USA. Units affected: 53,452 bottles.
Why was this product recalled?
Failed Impurities/Degradation Specifications: High out of specification impurity test results were obtained during stability testing.
Which agency issued this recall?
This recall was issued by the FDA Drug on May 28, 2014. Severity: Moderate. Recall number: D-1325-2014.